
Recursion Pharmaceuticals, Inc.: shareholders and insiders
Price
$2.72
November 17, 2026Market cap $1.7B
What Ploutos Investor adds for Recursion Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 29% since Nov 2, 2026, when the 10-Q these figures come from was filed ($3.83 then, $2.72 on Nov 17, 2026). The figures date from before that move.10-Q
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Class A StockShare of class8.50%
- ARK Investment Management LLCwith 1 more personClass A Common StockShare of class7.25%
- Vanguard Portfolio ManagementShare of class5.97%
- State StreetShare of class5.60%
- Vanguard Capital ManagementShare of class5.09%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc.Class A Stock | 8.50% | 44.54M | Jul 29, 20263 filings since Feb 5, 2025 | 13G/A | |
| ARK Investment Management LLCwith 1 more personClass A Common Stock | 7.25% | 37.32M | Feb 3, 20262 filings since Feb 14, 2025 | 13G/A | |
| Vanguard Portfolio Management | 5.97% | 31.37M | Jul 31, 2026 | 13G | |
| State Street | 5.60% | 30.00M | Nov 10, 20263 filings since May 12, 2026 | 13G | |
| Vanguard Capital Management | 5.09% | 26.74M | Jul 31, 2026 | 13G |
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Bridgewater (Dalio)In the quarter
- Citadel Advisors (Griffin)In the quarter-79%
- Millennium Mgmt (Englander)In the quarter-30%
- D.E. ShawIn the quarter-18%
- AQR CapitalIn the quarter+73%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Bridgewater (Dalio) | 37.7K | $100.0K | 0.00% | |
| Citadel Advisors (Griffin) | 128.5K | -79% | $500.0K | 0.00% |
| Millennium Mgmt (Englander) | 1.83M | -30% | $6.7M | 0.00% |
| D.E. Shaw | 37.9K | -18% | $100.0K | 0.00% |
| AQR Capital | 422.1K | +73% | $1.5M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 26.0% of its shares outstanding were held short, +2.5% since the report before.
- Shares held short
- 162M
- 26.0%
- Since the report before158M on Sep 30, 2026
- +2.5%
- 4.4
- 36.46M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 54%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 33.05M
- Nov 15, 2023: Shares held short 35.50M
- Nov 30, 2023: Shares held short 35.92M
- Dec 15, 2023: Shares held short 37.02M
- Dec 29, 2023: Shares held short 37.04M
- Jan 12, 2024: Shares held short 38.09M
- Jan 31, 2024: Shares held short 38.27M
- Feb 15, 2024: Shares held short 38.24M
- Feb 29, 2024: Shares held short 42.82M
- Mar 15, 2024: Shares held short 43.52M
- Mar 28, 2024: Shares held short 39.76M
- Apr 15, 2024: Shares held short 38.70M
- Apr 30, 2024: Shares held short 40.50M
- May 15, 2024: Shares held short 42.37M
- May 31, 2024: Shares held short 43.64M
- Jun 14, 2024: Shares held short 44.93M
- Jun 28, 2024: Shares held short 44.92M
- Jul 15, 2024: Shares held short 49.33M
- Jul 31, 2024: Shares held short 50.37M
- Aug 15, 2024: Shares held short 54.15M
- Aug 30, 2024: Shares held short 56.03M
- Sep 13, 2024: Shares held short 59.16M
- Sep 30, 2024: Shares held short 62.58M
- Oct 15, 2024: Shares held short 59.44M
- Oct 31, 2024: Shares held short 62.43M
- Nov 15, 2024: Shares held short 64.57M
- Nov 29, 2024: Shares held short 67.85M
- Dec 13, 2024: Shares held short 67.10M
- Dec 31, 2024: Shares held short 73.74M
- Jan 15, 2025: Shares held short 67.86M
- Jan 31, 2025: Shares held short 63.75M
- Feb 14, 2025: Shares held short 75.45M
- Feb 28, 2025: Shares held short 80.72M
- Mar 14, 2025: Shares held short 86.42M
- Mar 31, 2025: Shares held short 88.50M
- Apr 15, 2025: Shares held short 94.52M
- Apr 30, 2025: Shares held short 93.12M
- May 15, 2025: Shares held short 104M
- May 30, 2025: Shares held short 109M
- Jun 13, 2025: Shares held short 120M
- Jun 30, 2025: Shares held short 117M
- Jul 15, 2025: Shares held short 116M
- Jul 31, 2025: Shares held short 118M
- Aug 15, 2025: Shares held short 122M
- Aug 29, 2025: Shares held short 124M
- Sep 15, 2025: Shares held short 132M
- Sep 30, 2025: Shares held short 133M
- Oct 15, 2025: Shares held short 126M
- Oct 31, 2025: Shares held short 129M
- Nov 14, 2025: Shares held short 146M
- Nov 28, 2025: Shares held short 152M
- Dec 15, 2025: Shares held short 154M
- Dec 31, 2025: Shares held short 166M
- Jan 15, 2026: Shares held short 163M
- Jan 30, 2026: Shares held short 166M
- Feb 13, 2026: Shares held short 173M
- Feb 27, 2026: Shares held short 169M
- Mar 13, 2026: Shares held short 174M
- Mar 31, 2026: Shares held short 174M
- Apr 15, 2026: Shares held short 174M
- Apr 30, 2026: Shares held short 171M
- May 15, 2026: Shares held short 184M
- May 29, 2026: Shares held short 164M
- Jun 15, 2026: Shares held short 184M
- Jun 30, 2026: Shares held short 172M
- Jul 15, 2026: Shares held short 181M
- Jul 31, 2026: Shares held short 181M
- Aug 14, 2026: Shares held short 178M
- Aug 31, 2026: Shares held short 179M
- Sep 15, 2026: Shares held short 179M
- Sep 30, 2026: Shares held short 158M
- Oct 15, 2026: Shares held short 162M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading54.9% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 54.9% of the shares in the reported trades were short sales, against 49.7% in the 14 before.
- Last 14 sessionsOct 29, 2026 – Nov 17, 2026
- 54.9%
- The 14 beforeOct 9, 2026 – Oct 28, 2026
- 49.7%
- Change
- +5.2 pts
- Short sales a dayon average, of 11.39M shares
- 6.25M
- More than atof 3,666 US-listed companies, same days
- 67%
- Median of alleight in ten from 34.6% to 63.7%
- 50.3%
- Short sales
- Oct 9, 2026: Short sales 43.5%
- Oct 12, 2026: Short sales 56%
- Oct 13, 2026: Short sales 58.2%
- Oct 14, 2026: Short sales 44.5%
- Oct 15, 2026: Short sales 50.1%
- Oct 16, 2026: Short sales 52.2%
- Oct 19, 2026: Short sales 57.5%
- Oct 20, 2026: Short sales 58.4%
- Oct 21, 2026: Short sales 46.4%
- Oct 22, 2026: Short sales 48.6%
- Oct 23, 2026: Short sales 50.9%
- Oct 26, 2026: Short sales 52%
- Oct 27, 2026: Short sales 33.4%
- Oct 28, 2026: Short sales 45.8%
- Oct 29, 2026: Short sales 39%
- Oct 30, 2026: Short sales 50%
- Nov 2, 2026: Short sales 45%
- Nov 3, 2026: Short sales 41%
- Nov 4, 2026: Short sales 46.4%
- Nov 5, 2026: Short sales 55%
- Nov 6, 2026: Short sales 39.3%
- Nov 9, 2026: Short sales 44%
- Nov 10, 2026: Short sales 69.5%
- Nov 11, 2026: Short sales 50%
- Nov 12, 2026: Short sales 61.5%
- Nov 13, 2026: Short sales 61.8%
- Nov 16, 2026: Short sales 66.7%
- Nov 17, 2026: Short sales 72%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- ARKGARK Genomic Revolution ETFWeight in the fund2.63%
- ARKKARK Innovation ETFWeight in the fund1.09%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.76%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.46%
- IBBiShares Biotechnology ETFWeight in the fund0.13%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.11%
- IWMiShares Russell 2000 ETFWeight in the fund0.06%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.06%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.05%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.04%
21 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 323
- Q4 2025: Managers 335
- Q1 2026: Managers 338
- Q2 2026: Managers 344
Institutional investors by quarter
The fund managers holding RXRX, quarter by quarter, from Q1 2019 to Q2 2025, 26 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 344 managers held 362M shares, worth $1.3B. During the quarter 52 opened a position, 46 closed one, 127 added and 98 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+16%
- ARK Investment ManagementIn the quarter+2.8%
- State StreetIn the quarter+22%
- Vanguard Portfolio ManagementIn the quarter+37%
- Baillie GiffordIn the quarter-0.8%
- Vanguard Capital ManagementIn the quarter+2.3%
- Geode Capital ManagementIn the quarter+13%
- Softbank GroupIn the quarter
- MIC Capital Management UKIn the quarter
- UBS GroupIn the quarter+75%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 50.30M | +16% | $185M |
| ARK Investment Management | 41.34M | +2.8% | $152M |
| State Street | 34.71M | +22% | $127M |
| Vanguard Portfolio Management | 31.13M | +37% | $114M |
| Baillie Gifford | 23.49M | -0.8% | $86M |
| Vanguard Capital Management | 22.77M | +2.3% | $84M |
| Geode Capital Management | 13.82M | +13% | $51M |
| Softbank Group | 13.64M | $50M | |
| MIC Capital Management UK | 9.64M | $35M | |
| UBS Group | 8.95M | +75% | $33M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Recursion Pharmaceuticals's filings show?
Who buys and sells is one part of Recursion Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold RXRX?
5 of the managers we track held the shares on Jun 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $6.7M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.